Biohaven Ltd. (NYSE: BHVN) saw its shares climb 8.5% on Wednesday after releasing preliminary results from two ongoing Phase 1b studies of experimental protein-degrading therapies for autoimmune conditions.
The company reported that BHV-1300 achieved mean reductions of pathogenic TSHR-IgG1 autoantibodies exceeding 80% over a 12-week period in patients diagnosed with Graves' hyperthyroidism. Clinical observations noted that participants experiencing overt hyperthyroidism reached normalization of thyroid hormone levels within weeks of dosing, with median times to normalization of T4 at 3 weeks and T3 at 5 weeks following the first administration.
Separately, Biohaven said BHV-1400 produced a rapid mean reduction in Gd-IgA1 of approximately 60% within hours after dosing and reached a mean reduction near 70% within the first month in patients with IgA nephropathy. Preliminary clinical indicators accompanying these antibody reductions included an increase in estimated glomerular filtration rate (eGFR), declines in spot urine protein-to-creatinine ratio (UPCR), and reduced hematuria, all observed with one month or less of dosing.
Both candidate therapies were evaluated in Phase 1b cohorts and demonstrated a differentiated safety profile in these early data. Biohaven reported no clinically significant increases in cholesterol, no meaningful decreases in albumin, and no clinically significant elevations in liver enzymes ALT, AST, or bilirubin. Most adverse events were described as mild and self-resolving; there were no drug discontinuations and no serious or severe adverse events reported in the datasets presented.
Biohaven indicated plans to initiate pivotal Phase 3 trials for both the Graves' disease and IgA nephropathy programs by mid-2026. The company said the registrational trials will employ a patient-friendly, self-administered autoinjector format.
Raymond James analyst Chris Raymond reiterated a Strong Buy rating on Biohaven and maintained a $50.00 price target. Raymond noted that although the current datasets are limited to a small number of patients, both programs show deep autoantibody depletion that is in-line with or faster than chief competitors, and that the degraders have so far been well tolerated. He added that Biohaven plans to begin pivotal trials in mid-2026 and that additional data and commentary were expected at the company's R&D day.
Key points
- BHV-1300 produced mean pathogenic TSHR-IgG1 reductions greater than 80% over 12 weeks; thyroid hormone normalization medians were 3 weeks for T4 and 5 weeks for T3. - Sector impact: biotech, healthcare, capital markets for biopharma.
- BHV-1400 achieved roughly 60% mean Gd-IgA1 reduction within hours and about 70% within one month, with early signals of improved kidney measures (eGFR up, UPCR and hematuria down). - Sector impact: nephrology therapeutics, clinical-stage biotech.
- Both candidates displayed favorable early safety profiles in Phase 1b, with mostly mild adverse events and no serious or severe events reported.
Risks and uncertainties
- Data derive from ongoing Phase 1b studies with a small number of patients, which limits the ability to generalize efficacy and safety outcomes. - Impacted sectors: clinical development, biotech investors.
- Findings are preliminary and early-stage; outcomes in larger, pivotal studies could differ from these initial observations. - Impacted sectors: drug development, equity markets for biopharma.
- Although early safety signals are favorable, longer-term tolerability and potential safety issues may emerge in larger or longer-duration trials. - Impacted sectors: regulatory review, healthcare payers.
Investors and market participants will be watching Biohaven's progress as the company prepares to move both programs into registrational Phase 3 trials by mid-2026 and as it provides further data at its R&D day.